As measured by STAT1 phosphorylation via immunoblotting, tofacitinib significantly reduced P-STAT1 levels in primary ALS and control NK cells versus those stimulated with IL-2 and IL-15 (Figure 3A). This evidence concerns the gene IL2 and amyotrophic lateral sclerosis.